Trabeculectomy With Mitomycin-C Versus Trabeculectomy With Amniotic Membrane Transplant: A Medium-term Randomized, Controlled Trial

By Next Biosciences 3 years ago
Home  /  Medical Articles  /  Trabeculectomy With Mitomycin-C Versus Trabeculectomy With Amniotic Membrane Transplant: A Medium-term Randomized, Controlled Trial

Hany A. Khairy, FRCEd, FRCSG, MD and Moataz F. Elsawy, MD
J Glaucoma, Volume 00, Number 00, 2014

Purpose: To evaluate the intraocular pressure (IOP)-lowering effect of trabeculectomy with the use of amniotic membrane transplant (AMT) compared with the standard trabeculectomy with Mitomycin- C (MMC) in patients with primary open-angle glaucoma.

  • Patients and Methods: This study was a patient-masked, randomized, controlled comparison trial involving 52 eyes of 52 patients with bilateral primary open-angle glaucoma. Patients were randomized to receive trabeculectomy with AMT or trabeculectomy with MMC. The main outcome for comparison was the IOP-lowering effect of both procedures. Surgical success was considered if the patient’s IOP was 20% without the use of any medication.
  • Results: All surgeries passed uneventfully without intraoperative complications, and all patients showed significantly (P<0.05) lower IOP on the first postoperative day compared with their respective preoperative IOP with non-significant (P>0.05) difference between both study groups. All patients, irrespective of the operative procedure maintained significantly (P<0.05) lower IOP compared with their respective preoperative IOP till the end of 24 months follow-up. Moreover, patients of the AMT group showed lower IOP compared with those included in the MMC group throughout the follow-up period; however, the difference was not statistically significant at any point of the study period.
  • Conclusions: AMT exhibits potential as an alternative to MMC in trabeculectomy surgery. Over 24 months of follow-up, the use of AMT with trabeculectomy was safe and effective with an IOP-lowering effect comparable to that achieved with the use of MMC, and a reduced rate of postoperative complication.
Category:
  Medical Articles
this post was shared 0 times
00
About

 Next Biosciences

  (30 articles)

Please note that we are currently experiencing problems with our phone lines and internet.

Kindly call us on 084 664 4646 for Netcells and 082 386 5289 for Genetics.